Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development
MV Holmes, TG Richardson, BA Ference… - Nature Reviews …, 2021 - nature.com
Drug development in cardiovascular disease is stagnating, with lack of efficacy and adverse
effects being barriers to innovation. Human genetics can provide compelling evidence of …
effects being barriers to innovation. Human genetics can provide compelling evidence of …
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development.
MV Holmes, TG Richardson, BA Ference… - Nature reviews …, 2021 - europepmc.org
Drug development in cardiovascular disease is stagnating, with lack of efficacy and adverse
effects being barriers to innovation. Human genetics can provide compelling evidence of …
effects being barriers to innovation. Human genetics can provide compelling evidence of …
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development
MV Holmes, TG Richardson… - Nature reviews …, 2021 - pubmed.ncbi.nlm.nih.gov
Drug development in cardiovascular disease is stagnating, with lack of efficacy and adverse
effects being barriers to innovation. Human genetics can provide compelling evidence of …
effects being barriers to innovation. Human genetics can provide compelling evidence of …
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development
MV Holmes, TG Richardson… - Nature Reviews …, 2021 - research-information.bris.ac.uk
Drug development in cardiovascular disease is stagnating, with lack of validated targets a
major roadblock to innovation. Human genetics can provide compelling evidence of …
major roadblock to innovation. Human genetics can provide compelling evidence of …
[引用][C] Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development
MV Holmes, TG Richardson, BA Ference… - Nature Reviews …, 2021 - cir.nii.ac.jp
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug
development | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
development | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development
MV Holmes, TG Richardson… - Nature Reviews …, 2021 - search.proquest.com
Drug development in cardiovascular disease is stagnating, with lack of efficacy and adverse
effects being barriers to innovation. Human genetics can provide compelling evidence of …
effects being barriers to innovation. Human genetics can provide compelling evidence of …